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Infectious diseases of viral, bacterial and haemoparasitic origin are 
clinically important and commonly encountered among companion 
animals. Of the various etiologies, virus imposes serious disease in both 
dogs and cats. In India, these viral diseases viz canine parvoviral enteritis, 
canine distemper, rabies, feline panleukopenia, rhinotracheitis and calici 
viral infections are life-threatening and endemic diseases in dogs and cats 
even with the availability of vaccines. Various attributes like semi and free 
ranging pattern of dogs and cats along with uncontrolled population with 
poor husbandry practices, lack of implementation of prevention and control 
strategies, epidemiology, global climatic variation, increased susceptibility, 
vaccination failures, lack of knowledge on early diagnosis, misdiagnosis, and 
lack of awareness among the pet parents are the influencing determinants 
for the endemicity of the above said diseases in our country. Globally, efforts 
to control some of these viral diseases have been achieved by implementing 
strict vaccination schedule and Veterinary services.  In India, vaccines 
against CPV 2, corona, rabies, kennel cough, panleukopenia, calici, and 
rhinotracheitis are readily available, but how it is used successfully in the 
field is a question of concern.  As a forerunner in Veterinary Science we at the 
department of Veterinary Preventive Medicine, MVC is currently focussing on 
molecular epidemiology, disease forecasting models, diagnostic 
approaches, and vaccine studies on various infectious diseases of 
companion animals continuously to aid in the treatment and devising 
control strategies. This e-conference was initiated with the aim to integrate 
Veterinary scientist, faculties, research scholars, practitioners, students and 
pet parents to discuss on important developments and challenges 
happening in India and Global level on these viral diseases of dogs and cats 
through this virtual platform during this pandemic situation.
play a pivotal role in breaking the transmission cycle of 
infectious agents in pets by implementing appropriate vaccination 
schedules and biosecurity measures. In this context, educating the pet 
parents about recent updates on vaccination and bioscecurity measures is 
of prime importance to create awareness.  In continuation of past successful 
pet parents meet,  this year we are organizing  NATIONAL PET PARENTS MEET  
for the benefit of pet owners through online mode on 02.12.2020. 
Tamil Nadu Veterinary and Animal Sciences University (TANUVAS) is one of 
the leading Universities among Veterinary and Animal Sciences University. 
Madras Veterinary College (MVC) is one of the pioneering oldest and 
constituent institute of TANUVAS started way back in 1903. Department of 
Veterinary Preventive Medicine was first of its kind started in the year 1958 at 
MVC and it is focussing on teaching and research on various infectious 
diseases of farm and companion animals. Till now more than 200 research 
scholars have graduated from this prestigious department. This department 
is currently working on molecular epidemiology, disease forecasting 
models, and vaccine studies on canine viral diseases, brucellosis, 
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Introduction 
The most recent companion animal vaccination guidelines that consider the needs of both 
dogs and cats worldwide were produced by the World Small Animal Veterinary Association 
(WSAVA) Vaccination Guidelines Group (VGG) and published in the Journal of Small Animal 
Practice in January 2016.1  The most recent guidelines dealing with dogs only were published 
in 2017 by the American Animal Hospital Association (AAHA) and slightly updated in 2018.2  
The AAHA guidelines are primarily intended for North American readers but parts of the 
document are more broadly relevant.  This year, 2020, AAHA teamed up with the American 
Association of Feline Practitioners (AAFP) and produced updated feline vaccination 
guidelines.3  Other valuable guidelines have been published by the European Advisory Board 
on Cat Diseases (ABCD).4   
 
Although these groups develop their guidelines independently of one other, there is much 
consensus in their recommendations.5 All of these guidelines include multiple tables that 
provide the fine details about when and how to use vaccines to best effect.  The WSAVA 
guidelines contain more than 100 frequently asked questions. These tables and FAQs are well 
worth careful scrutiny.  Table 1, below, provides links to the guidelines produced by these 
organisations and also shows the dates guidelines were published, going back to the first ones 
produced by AAFP in 1998.  
 








Link to their most recent guidelines 
AAFP 1998, 2000, 
2006, 2013 
Cats https://journals.sagepub.com/doi/pdf/10.1177/1098612X13500429  
AAHA/AAFP 2020 Cats https://catvets.com/guidelines/practice-guidelines/aafp-aaha-feline-
vaccination 
AAHA 2003, 2006, 
2007, 2011, 
2017 
Dogs https://www.aaha.org/guidelines/canine_vaccination_guidelines.aspx  
WSAVA 2007, 2010, 
2016 
Both https://www.wsava.org/guidelines/vaccination-guidelines  
ABCD 2009, 2013, 
2015, 2017 
Cats http://www.abcdcatsvets.org/guidelines/  
Abbreviations: AAFP, American Association of Feline Practitioners; AAHA, American Animal Hospital Association; WSAVA, 
World Small Animal Veterinary Association; ABCD, European Advisory Board on Cat Diseases. 
 
The latest WSAVA Vaccination Guidelines are freely available in multiple languages via the 
WSAVA website (https://www.wsava.org/guidelines/vaccination-guidelines). At that address 
there are additional resources, including some for owners and breeders.  The same is true of 
the updated AAHA/AAFP feline vaccination resources page.  
 
Potted history about companion animal vaccination guidelines 
The previously-widespread practice of vaccinating every adult dog and cat against 
“everything” every year was never based on scientific evidence of need.6 In the early days of 
canine distemper vaccines, the possible need for repeated vaccination(s), beyond the primary 
puppy course, was discussed vigorously by veterinarians but little scientific evidence was 
available for consideration. There was some early evidence of robust, long-lasting protection 
afforded by vaccination against distemper7 and next to nothing to the contrary.  Nevertheless, 
a few sets of guidelines were developed from the 1970s onwards, based loosely on what was 
being done by practitioners (mostly in North America), rather than upon scientific evidence or 
basic immunological principles. A few pet owners and many veterinary immunologists knew 
that annual revaccination against “everything” was not soundly based upon evidence, but their 
concerns, writings8 and public statements on the subject were largely ignored.   
 
In 1991-1993 it was first recognised that feline leukaemia virus and rabies vaccines could 
(rarely) cause injection site sarcomas in cats. These rare tumours were very difficult to manage 
successfully and often led to the cat’s death. Later, it was shown that other vaccines and 
injected substances could also cause these malignancies (feline injection site sarcomas; 
FISS).  The veterinary profession in USA responded within a few years by producing 
guidelines for the use of vaccines in cats that were more science-based than had previously 
been the case. The American Association of Feline Practitioners (AAFP) was, unsurprisingly, 
the first professional group to produce such a set of guidelines (in 1998). The AAHA followed 
soon afterwards (2003) with canine vaccination guidelines.  The first WSAVA Guidelines 
(authored by the Vaccination Guidelines Group; VGG) were published in 2007. European cat 




Core and non-core vaccines 
A key feature of all of these guidelines is that vaccines are classified as core (all animals 
should receive), non-core (optional, use is based on a risk-benefit analysis) and not 
recommended (insufficient evidence to justify use).  Rabies vaccines should be viewed as 
core or mandatory for both dogs and cats in countries where rabies is endemic. 
• Globally, the core vaccines for dogs protect against canine distemper virus (CDV), 
canine parvovirus (CPV) and canine adenovirus (CAV).  Vaccines contain CAV-2, 
which provides protection against both CAV-1 and CAV-2. 
• The main non-core vaccines available for dogs protect against canine infectious 
respiratory disease complex (CIRDC) and leptospirosis.  The CIRDC vaccines contain 
one or more of Bordetella bronchiseptica, CAV-2 and canine parainfluenza virus. In 
North America, separate canine influenzavirus vaccines are available.  Antigens 
related to other causes of CIRDC are not yet included.  There are numerous different 
non-core leptospira vaccines containing from 1 to 4 different serovars, protecting 
against members of 1 to 4 different serogroups.  In many countries, veterinarians 
recommend that every dog should be protected against leptospirosis.  In some 
countries, non-core vaccines to protect against Borrelia burgdorferi are available. 
• The canine enteric coronavirus vaccine is not recommended by WSAVA, nor AAHA, 
because of insufficient evidence of efficacy. 
 
• Globally, the feline core vaccines protect against feline panleukopenia virus (feline 
parvovirus; FPV), feline herpesvirus-1 (FHV-1) and feline calicivirus (FCV). 
• There are multiple non-core feline vaccines protecting against Chlamydia felis, feline 
leukaemia virus (FeLV) and (in some countries) feline immunodeficiency virus (FIV). 
• The vaccine intended to protect cats against feline infectious peritonitis (FIP) is 
designated as not recommended by WSAVA and AAHA/AAFP because of insufficient 
evidence of efficacy.  
 
• Other not recommended vaccines against Giardia and ringworm are available for dogs 
and or cats in some countries. 
 
 
The most recent updates to the WSAVA VGG guidelines 
For those familiar with previous guidelines, the most significant updates in the latest WSAVA 
guidelines9 are as follows: 
 
1.  The recommended timing of the last primary kitten and puppy vaccine is adjusted upwards 
from 14–16 weeks of age to 16 weeks of age or later. The decision to make this change was 
based on further evidence from the field that maternal antibodies can sometimes cause 
interference, in both puppies and kittens, even at 14 weeks of age and beyond.10-12  Indeed, 
in one rather alarming peer-reviewed publication, 36.7% of kittens did not seroconvert to feline 
parvovirus after vaccination at the ages of eight, 12 and 16 weeks.12  In another study, a total 
of 15%, 44% and 4% of repeatedly-vaccinated kittens had insufficient serological evidence of 
active immunity against FPV, FHV and FCV, respectively, at 17 weeks of age.10  Interestingly, 
on this particular topic, less published evidence is available for puppies than for kittens.11  
THESE SOMETIMES LONG-LASTING, INTERFERING MATERNAL ANTIBODIES CAN 
PREVENT SUCCESSFUL IMMUNIZATION, AND ARE CONSIDERED TO BE THE MAJOR 
CAUSE OF APPARENT VACCINATION FAILURES IN MANY COUNTRIES.  In many cases 
of apparent vaccination failure, the final puppy / kitten vaccination was given too early, before 
the animal reached the age of 16 weeks. 
2.  The “first annual booster” is reconsidered, including its name, in light of what it is thought 
to actually achieve immunologically.  Its main purpose is to immunize the minority of animals 
that failed, earlier, to respond actively to one or more vaccine components, even if vaccinated 
at 16+ weeks of age.  This failure is almost invariably a consequence of passively-transferred, 
maternal interfering antibodies.  WSAVA guidelines recommend that the “first annual booster” 
BE RECONSIDERED AND RESCHEDULED EARLIER, MOVING IT FROM 12–16 MONTHS 
TO 6–12 MONTHS OF AGE. This vaccination should be renamed and considered as the last 
of the “puppy or kitten vaccinations”.  Why should we leave the window of opportunity for these 
pathogens open for longer than is necessary in those unfortunate individuals that failed to 
mount an active immune response earlier? 
3.  “Low risk” and “high risk” situations and feline lifestyles are more thoroughly described.  
Spending time in a boarding cattery is now explicitly designated as “high risk”.  This has 
implications for the use of feline respiratory virus vaccines.  FHV and FCV vaccine should be 
given annually to cats that regularly visit boarding catteries. Administration of the vaccine in 
the weeks leading up to the cattery visit, rather than (say) many months earlier would be 
advisable. 
4.  There is updated consideration of the possible anatomical sites for injection of vaccines 
(perhaps in particular adjuvanted vaccines) in cats.  This includes brief consideration of distal 
tail vaccination.  Tail vaccination has been reported to be surprisingly well tolerated by cats.13  
The distal limbs are another suitable site, strongly recommended in the latest AAHA/AAFP 
guidelines.3 
5.  The guidelines are much more thoroughly referenced, although there is scope for further 
improvement.  Quality of evidence is considered using a novel system specifically developed 




Antibody testing (or “titre testing”) relies upon the detection of antibodies in the patient, 
generally in its serum, to judge whether it is already protected against disease and therefore 
does not need to be revaccinated. Antibody testing is used extensively in humans, for example 
to determine whether a previously-vaccinated person needs revaccination against rabies.  The 
use of antibody testing in companion animals is an extension of its use in humans.  Some 
clients would not want themselves or their children unnecessarily vaccinated or revaccinated 
if they were already protected.  They would not want to take the (albeit usually small) risk of 
an adverse event.  They would be prepared to pay “extra” to find out their status and only 
receive vaccination or revaccination if required.  Indeed, they may have no choice in the 
matter.  The medical system may require this approach to be taken.  Some clients extend their 
views about vaccination of human family members to their dogs and cats.  Some veterinarians 
feel strongly that vaccination in the face of pre-existing immunity is an unnecessary, potentially 
harmful medical procedure.  Others cite the low incidence of serious vaccine-associated 
adverse effects14 and are less concerned. 
 
Titre testing is only relevant to some of the vaccines we administer. That is because antibody 
presence correlates reliably with protection (at least in one direction, presence indicating 
protection) only for some infectious agents.  Titre testing is most relevant to FPV and the three 
canine core vaccines (those against the CPV-2 variants, canine adenoviruses 1 and 2, and 
canine distemper virus, CDV).  For these viruses, presence of antibody in an adult reliably 
predicts that the animal is protected.  Animals that lack antibody, or have so little that the test 
in use cannot detect antibody, may nevertheless be protected by memory B cells or cellular 
immunity, but the safest assumption in that situation would be that the animal lacks protection, 
and therefore should be revaccinated out of an abundance of caution.  Antibodies against 
feline herpesvirus-1 and feline calicivirus are, overall, less reliable indicators of protection 
against disease and are not widely used to make judgements about the need, or otherwise, 
for revaccination of adult cats against these viruses. 
 
For the moment, antibody testing is relatively expensive, but it is becoming increasingly 
convenient and less expensive for veterinarians to choose this option if they or their clients 
are inclined to do so.  The risk of vaccinating dogs unnecessarily with core, non-rabies 
vaccines has been reported to be very low14 but this does not discourage some owners from 
requesting “titre testing”. 
 
“Titre testing” is another example of a name that we should encourage to disappear soon 
(along with “first annual booster”).  Most veterinarians would find “quantitative antibody testing” 
and “qualitative antibody testing” more straightforward and self-explanatory.  A titre is a 
measure of dilution, in this case, of serum antibodies.  Strictly speaking, titre testing is 
quantitative antibody testing, done mostly in diagnostic laboratories.  If a large concentration 
of an antibody is present in serum, the serum can be diluted a great deal, for example, 640-
fold in the case of CPV (a “high titre”) and the effects of that antibody (for example, virus 
neutralization or inhibition of haemagglutination) can still be detected.  Laboratories can 
provide a true antibody titre, if the veterinarian needs to know the amount of antibody present.  
In contrast, an increasing number of in-practice antibody detection tests report only positive / 
negative results, so the use of the word “titre” in that setting is inappropriate.  In addition, for 
some important vaccine-preventable diseases, mere presence of detectable antibody (not the 
amount) in adult animals is reported to correlate with robust protection.  So the in-practice, 
qualitative tests that produce a positive or negative result can be of substantial practical value.  
We often do not require the rigour of quantitation.  Conversely, the titre (or amount) of antibody 
does matter a great deal in puppies and kittens, before they mount their own active immune 
responses.  A large amount (i.e. a high titre) of maternally-derived antibody would interfere 
more and for longer with attempts to immunize than would a smaller amount (or lower titre) of 
antibody. 
 
Further well-written details about the indications and interpretation of qualitative (plus/minus) 
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Outline of this talk
• Core and non-core vaccines
• List the key take-home points
• Background: how did we get here?
• More scrutiny of those key points
• Q & A
Core and non-core vaccines
Core vaccines protect against…
•Canine distemper virus
•Canine adenovirus (1 & 2)
•Canine parvovirus-2 variants
•Rabies virus (where it is endemic)
All puppies should receive core vaccines, if at all possible, and all 
adult dogs should be managed in a way that maintains robust 
immunity against these infectious agents for life
CANINE
Non-core vaccines (optional) 
• Canine parainfluenzavirus
• Canine influenzavirus(es) (North America)
• Bordetella bronchiseptica
• Leptospira serovars (contents vary by region)
• Canine enteric coronavirus
CANINE
Not recommended




•Rabies virus (where it is endemic)
FELINE
All kittens should receive core vaccines, if at all possible, and all 
adult cats should be managed in a way that maintains robust 
immunity against these infectious agents for life
Non-core vaccines (optional) 
• Feline leukaemia virus (FeLV)
• Chlamydia felis
• Bordetella bronchiseptica (some markets)
• Feline immunodeficiency virus (FIV)




List of key take-home points 
about canine and feline vaccines 
and vaccinations
What are the key points?
1. Good quality, well kept canine core vaccines and 
FPV vaccine provide very long-lasting protection.  
Non-core vaccines, much less so
2. The last of the “primary” kitten and puppy 
vaccines should be given no earlier than 16 
weeks of age.
3. The “first annual booster” (so-called) should be 
reconsidered.  It should be delivered at 26 - 52 
weeks of age
What are the key points?
4. “Low risk” and “high risk” lifestyles of cats need 
to be considered.  This is especially relevant to 
the core feline respiratory virus vaccines, FHV-1 
and FCV.
5. Anatomical sites for injection of vaccines into cats 
need to be reconsidered with safety in mind
Background:
how did we get to this point?
Vaccine hesitancy is not new






Declining “authority” of professions
World Wide Web







Long-ignored views of 
some vet immunologists
Why were we challenged so forcefully?
Feline injection site 
sarcomas (FISS)
Declining “authority” of professions
World Wide Web












Injections occasionally induce fibrosarcomas in cats
Hendrick MJ, Goldschmidt MH.  Journal of the American Veterinary Medical Association (1991) 
15;199(8):968. Hendrick MJ Goldschmidt M
Epidemiologic evidence
for a causal relation between vaccination 
and fibrosarcoma tumorigenesis in cats
Kass PH, Barnes WG, Spangler WL, et al.
Journal of the American Veterinary 
Medical Association (1993) 203: 396-405. 
Kass et al. 1993
• FeLV vaccine recipients were 2.78 - 5.49 times 
more likely to get a sarcoma at an injection site 
rather than elsewhere on their body
• Rabies vaccine recipients were 1.2 - 1.99 times 
more likely to get a sarcoma at an injection site 
rather than elsewhere on their body





Hydranencephaly and cerebellar 
hypoplasia in two kittens attributed to 
intrauterine parvovirus infection
Sharp NJ, Davis BJ, Guy JS, et al.
Journal of Comparative Pathology
121: 39-53 (1999)
“an in-utero parvovirus infection,
possibly due to vaccination”  [italics mine]
Other safety issues
Outbreak of fatal salmonellosis in cats 
following use of a high-titer modified-
live panleukopenia virus vaccine
Foley JE, Orgad U, Hirsh DC, et al
Journal of the American Veterinary Medical Association
(1999)  214: 67-70. 
Other safety issues
Abortion and death in pregnant bitches 
associated with a canine vaccine 
contaminated with bluetongue virus
Levings RL, Wilbur LA, Evermann JF
et al.
Developments in Biological Standardization
(1996)  88: 219-20.
Other safety issues
Vaccine-associated immune-
mediated hemolytic anaemia 
in the dog
Duval D, Giger U.
Journal of Veterinary Internal Medicine
10: 290-295.  (1996)
Other safety issues
The risks of adverse 
consequences are 
real but small
On the other side of the coin…
“Results demonstrated that recent vaccination 
(<3 months) does not increase signs of ill-health 
by more than 0.5% and may actually decrease it 
by as much as 5%.”
On the other side of the coin…
Continuing to revaccinate 
with core vaccines frequently
Is it safe?
Is it efficacious?
Is it scientifically justifiable?
i.e. does the necessity for frequent core vaccine boosters
stand up to scientific scrutiny?
DoI
Evidence
Duration of Immunity data
• Studied 30 dogs imported to Iceland, where 
there is no canine distemper
• Last vaccine given at 6 to 16 weeks of age, 10 of 
the 30 only ever received one vaccination
• Median time since last vaccine: 5.5 years
• At least 73.3% still had ‘protective’ titres ≥ 1:16
• That % compares favourably with dogs 
vaccinated annually
CDV: Olson et al. (1997)

144 adult dogs that had not been vaccinated 
in the last 3 to15 years.
• Protective Abs to CPV present in 95%
• Protective Abs toCDV in 71.5% 
• Protective Abs toCAV in 82%.
Pfizer.  Four years…
Revaccination of individual adult cats 
and dogs – why 3 years?
Explaining the key points
1. Last primary puppy and kitten vaccine goes up 
from 14 – 16 weeks to 16 weeks +
2. “First annual booster” (so called) in both species 
goes from 12 – 16 months to 26 – 52 weeks
3. “Low risk” and “high risk” feline lifestyles and 
situations are much better defined (especially 
relevant to the respiratory virus vaccines)
Effect of interfering 
maternal antibody
Effect of interfering 
maternal antibody
“Weaker” vaccine
Effect of interfering 
maternal antibody
Effect of interfering 
maternal antibody




…92.2% seroconverted to CPV after the 12-week vaccination.  Possible reasons 







1:320 highest puppy 
titre
2006
What does this 16 + week 
finish mean for the number 
of required primary puppy / 
kitten vaccinations?
http://wallpapersafari.com/w/TfhMHb http://cutepuppyclub.com/wp-content/uploads/2015/05/White-Cute-Puppy-.jpg
Explaining the key points
1. Last primary puppy and kitten vaccine goes up 
from 14 – 16 weeks to 16 weeks +
2. “First annual booster” (so-called) in both species 
goes from 12 – 16 months to 26 – 52 weeks
3. “Low risk” and “high risk” feline lifestyles and 
situations are much better defined (especially 
relevant to the respiratory virus vaccines)
“First annual booster”
• Change to 26 – 52 weeks of age
• The only immunological rationale for the 12-16 
month “booster” (when using modern MLV core 
vaccines) has been to catch the small 
percentage of puppies and kittens that fail to 
respond immunologically at 16 weeks.
• So why leave them open to infection until they 
are 12 – 16 months of age?
• Absolutely does not preclude a first annual 
health check
• The “first annual booster” needs a 
much better name, because…
1. It is not really a booster;
2. It is not the first in a series of annual revaccinations;  
3. VGG &AAHA/AAFP recommend it should not be 
delayed until the animal is 12 – 16 months of age; 
and
4. After it is given, revaccination against “core” agents 
needs to be done no more often than every 3 years in 
typical low risk situations
“First annual booster”
Explaining the updates
1. Last primary puppy and kitten vaccine goes up 
from 14 – 16 weeks to 16 weeks +
2. “First annual booster” (so called) in both species 
goes from 12 – 16 months to 26 – 52 weeks
3. “Low risk” and “high risk” feline lifestyles and 
situations are much better defined (especially 
relevant to the respiratory virus vaccines)
What is a “high risk” lifestyle for a 
cat?
• Cats that go into boarding catteries should be vaccinated 
against FCV / FHV-1 annually, with the injection preferably in 
the weeks or months leading up to boarding
Duration of Immunity (DoI) induced 
by feline respiratory virus vaccines
FPV, FHV-1, FCV
• Scott FW, Geissinger CM. (1997) Duration of 
immunity in cats vaccinated with an inactivated 
feline panleukopenia, herpesvirus and calicivirus 
vaccine. Feline Practice 25: 12-19.
• Scott FW, Geissinger CM. (1999) Long-term 
immunity in cats vaccinated with an inactivated 
trivalent vaccine. American Journal of Veterinary 
Research 60: 652-658.
Notwithstanding the title of this paper, vaccinated cats developed 
more significant illness than did the cats in the much earlier Scott & 
Geissinger study.  Control cats were worse affected than vaccinates, 
but protection was rather limited, esp. against FHV-1
2015
Notwithstanding the title of this paper, vaccinated cats developed more significant illness 
than did the cats in the much earlier Scott & Geissinger study.  Control cats were worse 
affected than vaccinates, but protection was rather limited, esp. against FHV-1
FHV-1
FCV
Notwithstanding the title of this paper, vaccinated cats developed more significant illness 
than did the cats in the much earlier Scott & Geissinger study.  Control cats were worse 
affected than vaccinates, but protection was rather limited, esp. against FHV-1
“After primary FeHV-1 infection, cats are largely resistant to disease following further 
challenge but after six months or more, protection may only be partial.”
“Thus in cats with a previously low risk of exposure going into a high risk situation such as a 
boarding or rescue shelter for example, annual vaccination might still be considered 
appropriate.”
“…the relative efficacy was shown to decrease from 95% shortly after primary vaccination,
to 52% after 7.5 years”.
Explaining the key points
4. Updated consideration of anatomical sites for 
injection of vaccines in cats


Surprisingly good tolerance reported in this study
Vaccination of animals in 
shelters
• Shelters are highly variable, no one-size-fits-all
• Generally high infectious disease risk
• Start core vaccines on admission, as early as 4 – 6 
weeks.  Revaccinate every 2 weeks until 20 weeks 
of age
• Can give an intranasal or oral Bordetella vaccine as 
early as 3 weeks of age
Antibody testing as an alternative to 
“automatic” revaccination or to 
provide guidance when making 
decisions
Antibody testing
• Antibody testing has been used to assess the risk of 
individuals becoming infected in outbreak situations in 
shelters
• Breeding bitches and queens have been tested >1 week 
before or after parturition with the aim of guiding 
vaccination decisions relating to their puppies / kittens
• Individual adults can be tested to determine whether 
revaccination is needed
• Most relevant to canine core vax  + FPV
Summary
• The most important vaccines that most dogs and cats ever receive are 
the core vaccines that they receive as puppies and kittens, especially 
the last in the primary series.
• Modern canine core vaccines and FPV vaccines are safe, effective and 
provide long-lasting protection
• Feline core respiratory virus vaccines do not provide such impressive 
protection as the other canine and feline core vaccines  
• Non-core vaccines have not been shown to provide such strong or 
long-lasting  protection and generally need to be given annually. 
Q & A
